PAVAJ Vascular was founded as part of the Mayo Clinic Employee Entrepreneurship Program. Several patents have been licensed from Mayo Clinic to Pavaj Vascular. The founder is an inventor of these patents. Pavaj Vascular has been founded to provide patients and clinicians with a groundbreaking innovation that decreases venous stenosis formation by coating AVFs with an anti-inflammatory. This leads to less blockage of the blood vessel and reduces the need for costly invasive procedures such as angioplasty, otherwise necessary to maintain patency and function when a patient’s autogenous arteriovenous fistula (AVF) is compromised by venous stenosis.

Our solution is designed to provide benefits for millions of patients worldwide who are facing issues related to hemodialysis for renal replacement therapy. It also has beneficial applications for those affected by angioplasty, PTFE AV grafts, coronary artery bypass grafts, arterial bypass grafts for peripheral arterial disease, coronary artery stents, PAD stents, and venous stents.

The participation of our team of clinical and scientific thought leaders and our research to date are indicators of the strong value of this innovative therapy. 

For reducing stenosis after placement of an AVF and after PTA, the US market size is estimated to be $6.4 billion. The worldwide AVF market is significantly larger, with approximately 4 million patients living with ESKD. When combined with other cardiovascular applications of this technology, the potential US market is estimated at $20 billion. The worldwide market for these therapies is much larger.